Long-term prognosis of patients with alcohol-related liver disease or non-alcoholic fatty liver disease according to metabolic syndrome or alcohol use.

ABSTRACT

BACKGROUND & AIMS: The boundary between non-alcoholic (NAFLD) and alcohol-related liver disease (ALD) is based on alcohol consumption. However, metabolic syndrome and alcohol use frequently co-exist. The aim of this study was to determine prognostic factors of long-term morbidity and mortality in patients with NAFLD or ALD. METHODS: From 2003 to 2016, all consecutive NAFLD or ALD patients were prospectively included in this cohort study. We evaluated overall survival, specific cause of mortality and occurrence of any complication. The primary endpoint was analysed by the Kaplan Meier method, secondary endpoints were estimated by Gray test method or logistic regressions. Factors independently associated with overall mortality and morbidity were identified by a multivariate Cox model. RESULTS: A total of 3365 patients (1667 with ALD and 1698 with NAFLD) were included. Median follow-up was 54 months (range 30-86) and 563 subjects died. In the overall population, overall mortality was higher in patients with ALD (HR 10.1 [7.57-13.3]), and with weekly alcohol consumption >7 units (HR1.66 [1.41-1.96]). Liver-related mortality was higher in patients with ALD (HR 11 [7.27-16.5]). In the NAFLD group, weekly alcohol consumption >1 unit was associated with higher overall mortality (HR 1.9 [1.1-3.4]), and weekly alcohol consumption >7 units was associated with higher overall morbidity (OR 1.89 [1.61-2.21]). In the ALD group, the presence of metabolic syndrome was associated with higher overall (HR1.27 [1.02-1.57]), and liver (HR 1.47 [1.1-1.96]) mortalities, and overall (OR 1.46 [1.14-1.88]), liver (OR 1.46 [1.14-1.88]) morbidities. CONCLUSION: In fatty liver diseases, light alcohol consumption and metabolic syndrome are prognosis cofactors.